ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing and gene insertion to develop new medicines. To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines. ReNAgade Therapeutics – RNA Without Limits
External link for ReNAgade Therapeutics
1 Broadway, 11th Floor
Cambridge, MA 02142, US
ReNAgade Therapeutics reposted this
ReNAgade has been acquired by Orna Therapeutics. With our combined capabilities, we aim to reshape the landscape of RNA-targeted therapies and modalities to explore new possibilities in CAR therapy, gene editing and more. Read more here: https://lnkd.in/eYHYAfkf #Biopharma #Science #Biotech
ReNAgade Therapeutics reposted this
Today is a landmark day in #RNA therapeutic research: ReNAgade has been acquired by Orna Therapeutics. The combination of industry-leading circular RNA sequencing and LNP delivery platforms positions Orna to expand development of RNA engineering and address the unmet needs of a range of diseases. Read more here: https://lnkd.in/eYHYAfkf #Biopharma #Science #Biotech
ReNAgade has been acquired by Orna Therapeutics. With our combined capabilities, we aim to reshape the landscape of RNA-targeted therapies and modalities to explore new possibilities in CAR therapy, gene editing and more. Read more here: https://lnkd.in/eYHYAfkf #Biopharma #Science #Biotech
Today is a landmark day in #RNA therapeutic research: ReNAgade has been acquired by Orna Therapeutics. The combination of industry-leading circular RNA sequencing and LNP delivery platforms positions Orna to expand development of RNA engineering and address the unmet needs of a range of diseases. Read more here: https://lnkd.in/eYHYAfkf #Biopharma #Science #Biotech
We are thrilled to welcome Siva Sakhamuri this week as our new Chief Technology Officer. With his exceptional leadership and expertise, our team eagerly anticipates working together to continue unlocking the potential of RNA medicines.
At #ASGCT2024, ReNAgade is presenting an oral and poster presentation highlighting preclinical data supporting our RNA technology platform. More information: https://bit.ly/4d6BBCG
This Saturday, ReNAgade CSO Pete Smith is presenting on recent discoveries in extra-hepatic delivery of #RNA cargoes and how ReNAgade’s portfolio of RNA delivery systems aim to overcome current limitations. More details: https://bit.ly/3PF798D
Tomorrow, our CEO Amit Munshi will participate in a fireside at the Evercore ISI Emerging Biotech Conference, where he will discuss ReNAgade’s multi-modal RNA platform and upcoming milestones. Webcast can be found here: https://bit.ly/3uMVDRs
Welcome Joseph Bolen, joining the team as ReNAgade’s Chief Scientific Innovation Officer. With over 45 years of experience in oncology and immunology, his leadership will be invaluable as we continue to drive our lead programs towards development milestones. Read here: https://bit.ly/3UR6bJX
At #JPM2024 next week, ReNAgade CEO Amit Munshi will present on the exciting updates we are making across our broad portfolio of novel RNA medicines. More details: https://bit.ly/48IpqJs